The markets opened lower with the Dow dropping 62 points to 20,028 as crude oil prices slipped. Nasdaq fell 15 points to 5,658.

On the upside

Cellect Biotechnology (Nasdaq: APOP) treated its first blood cancer patient in a Phase I/II trial of its stem cell technology ApoGraft.

Data from Diffusion Pharmaceuticals' (Nasdaq: DFFN) Phase 1/2 clinical trial evaluating the safety and efficacy of trans sodium crocetinate in newly diagnosed glioblastoma multiform has been published in the print edition of the Journal of Neurosurgery.

Myriad Genetics (Nasdaq: MYGN) reported better than expected earnings for the second quarter.

On the downside

Galena Biopharma (Nasdaq: GALE) priced its public offering of stock and warrants at the discounted price of $1.00 per unit.

Tidewater (NYSE: TDW) widened losses for the third quarter as revenue tumbled.

Investors locked in profits on Second Sight Medical Products (Nasdaq: EYES).

In the broad market, declining issues outpaced advancers by a margin of more than 5 to 3 on the NYSE and by nearly 5 to 2 on Nasdaq. The broader S&P 500 index lost 4 points to 2,288. Bitcoin fell $6 to $1,036.